Trial reportPloS one2014
Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia.
Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00097058 (Estrogen Use in Protection From Cognitive Decline), which is not on this map. Cited by 46 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Estrogen Use in Protection From Cognitive Decline
Who cites it
46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition.Frontiers in endocrinology · 2024Pooled it
- The historical progression of positron emission tomography research in neuroendocrinology.Frontiers in neuroendocrinology · 2023Pooled it
- Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer's disease and dementia.Frontiers in aging neuroscience · 2023Pooled it
- Long-term hormone therapy for perimenopausal and postmenopausal women.The Cochrane database of systematic reviews · 2017Pooled it
- Trial
- Trial
- Effects of Estradiol Withdrawal on Mood in Women With Past Perimenopausal Depression: A Randomized Clinical Trial.JAMA psychiatry · 2015Trial
- Review
- An imaging biomarker to detect non-glucogenic shift in brain energy metabolism in Alzheimer's disease.Journal of translational medicine · 2026Article
- DMN function changes on resting state fMRI in perimenopausal women.Open medicine (Warsaw, Poland) · 2026Article
- High glucose induces hippocampal neuron impairment through the SKP1/COX7C pathway: A potential mechanism for perimenopausal depression.Acta pharmaceutica Sinica. B · 2025Article
- Estradiol and Micronized Progesterone: A Narrative Review About Their Use as Hormone Replacement Therapy.Journal of clinical medicine · 2025Review
- Sexual and Metabolic Differences in Hippocampal Evolution: Alzheimer's Disease Implications.Life (Basel, Switzerland) · 2024Review
- Detection of sex-specific glutamate changes in subregions of hippocampus in an early-stage Alzheimer's disease mouse model using GluCEST MRI.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Sex as a Determinant of Age-Related Changes in the Brain.International journal of molecular sciences · 2024Review
- Estradiol enhanced neuronal plasticity and ameliorated astrogliosis in human iPSC-derived neural models.Regenerative therapy · 2024Article
- Review
- Sex-dependent gut microbiota-brain-cognition associations: a multimodal MRI study.BMC neurology · 2023Article
- Estrogen rapid effects: a window of opportunity for the aging brain?Neural regeneration research · 2022Review
- Ovarian steroid hormones: A long overlooked but critical contributor to brain aging and Alzheimer's disease.Frontiers in aging neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledThe objective of this study was to examine the effects of estrogen-based hormone therapy (HT) on regional cerebral metabolism in postmenopausal women (mean age = 58, SD = 5) at risk for development of dementia. The prospective clinical trial design included pre- and post-intervention neuroimaging of women randomized to continue (HT+) or discontinue (HT-) therapy following an average of 10 years of use. The primary outcome measure was change in brain metabolism during the subsequent two years, as assessed with fluorodeoxyglucose-18 positron emission tomography (FDG-PET). Longitudinal FDG-PET data were available for 45 study completers. Results showed that women randomized to continue HT experienced relative preservation of frontal and parietal cortical metabolism, compared with women randomized to discontinue HT. Women who discontinued 17-β estradiol (17βE)-based HT, as well as women who continued conjugated equine estrogen (CEE)-based HT, exhibited significant decline in metabolism of the precuneus/posterior cingulate cortical (PCC) area. Significant decline in PCC metabolism was additionally seen in women taking concurrent progestins (with either 17βE or CEE). Together, these findings suggest that among postmenopausal subjects at risk for developing dementia, regional cerebral cortical metabolism is relatively preserved for at least two years in women randomized to continue HT, compared with women randomized to discontinue HT. In addition, continuing unopposed 17βE therapy is associated specifically with preservation of metabolism in PCC, known to undergo the most significant decline in the earliest stages of Alzheimer's disease.
trial registrationClinicalTrials.gov NCT00097058.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.